



Diethelm Wallwiener

Contact

Diethelm Wallwiener

Publications (22)

Fehm T, Müller V, Banys-Paluchowski M, Fasching P, Friedl T, Hartkopf A, Huober J, Loehberg C, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Krawczyk N, Jaeger B, Reinhardt F, Hoffmann O, Müller L, Wimberger P, Ruckhäberle E, Blohmer J, Cieslik J, Franken A, Niederacher D, Neubauer H, Pantel K, Janni W, DETECT study group. Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial. *Clin Chem* 2024; 70:307-318.

Huebner H, Ruebner M, Kurbacher C, Hadji P, Hartkopf A, Lux M, Huober J, Uhrig S, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Wallwiener M, Müller V, Beckmann M, Hein A, Belleville E, Untch M, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Ettl J, Fasching P, Michel L. Return of individual genomic research results within the PRAEGNANT multicenter registry study. *Breast Cancer Res Treat* 2022

Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". *Breast* 2021; 55:138-139.

Huebner H, Beckmann M, Belleville E, Ruebner M, Untch M, Fasching P, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Müller V, Wallwiener M, Kurbacher C, Kuesters G, Hartkopf A, Lux M, Huober J, Volz B, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Ettl J. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. *BMC cancer* 2020; 20:1091.

Michel L, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran F, Lux M, Wallwiener D, Brucker S, Schneeweiss A, Wimberger P, Huebner H, Hartkopf A, Fasching P, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Volz B, Fehm T. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. *Cancers (Basel)* 2020; 12

Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. *Breast* 2020; 54:88-95.

Lux M, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Schneeweiss A, Belleville E, Beckmann M, Müller V, Nabieva N, Hartkopf A, Huober J, Volz B, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Brucker S. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. *Cancers (Basel)* 2018; 11

Lux M, Wallwiener M, Müller V, Beckmann M, Belleville E, Fehm T, Wallwiener D, Brucker S, Schneeweiss A, Luftner D, Huober J, Ettl J, Janni W, Hartkopf A, Nabieva N, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Fasching P. Update Breast Cancer 2017 - Implementation of Novel Therapies. *Geburtshilfe Frauenheilkd* 2017; 77:1281-1290.

Hartkopf A, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Brucker S, Belleville E, Beckmann M, Müller V, Huober J, Volz B, Nabieva N, Taran F, Schwitulla J, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lux M, Luftner D, Wallwiener M, Schneeweiss A. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. *Breast* 2017; 37:42-51.

Schramm A, Janni W, Wallwiener D, Taran F, Hartkopf A, Meier-Stiegen F, Pantel K, Schneeweiss A, Müller V, Alunni-Fabbroni M, Trapp E, Rack B, Huober J, De Gregorio N, Scholz C, Schochter F, Friedl T, Fehm T. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. *Arch Gynecol Obstet* 2015; 293:271-81.

Ruan X, Seeger H, Wallwiener D, Huober J, Mueck A. The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16 α -hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies. *Arch Gynecol Obstet* 2014; 291:1141-6.

Salmen J, Sohn C, Fehm T, Mohrmann S, Loehberg C, Hein A, Schulz-Wendtland R, Hartkopf A, Brucker S, Wallwiener D, Friese K, Hartmann A, Beckmann M, Janni W, Rom J, Heil J, Neugebauer J, Fasching P, Haeberle L, Huober J, Wöckel A, Rauh C, Schuetz F, Weissenbacher T, Kost B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum M, Rack B. Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. *Breast Cancer Res Treat* 2014; 148:143-51.

Banys M, Wallwiener D, Hirnle P, Wackwitz B, Kraemer B, Huober J, Becker S, Lueck H, Krawczyk N, Janni W, Gebauer G, Solomayer E, Fehm T. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. *BMC cancer* 2013; 13:480.

Hornung R, Becker S, Solomayer E, Kurek R, Banys M, Aydeniz B, Franz H, Wallwiener D, Fehm T. Optimal treatment for patients with ectopic pregnancies and a history of fertility-reducing factors. *Archives of gynecology and obstetrics* 2009; 283:41-45.

Zubke W, De Wilde R, Volz J, Wojdat R, Hammermüller U, Lobodasch K, Schmitz P, Werner C, Füllers U, Hucke J, Wässerer S, Hornung R, Wallwiener D. Bipolar coagulation with the BiClamp forceps versus conventional suture ligation: a multicenter randomized controlled trial in 175 vaginal hysterectomy patients. *Archives of gynecology and obstetrics* 2009; 280:753-60.

Kraemer B, Abele H, Hahn M, Wallwiener D, Rajab T, Hornung R. Cervical ectopic pregnancy on the portio: conservative case management and clinical review. *Fertility and sterility* 2008; 90:2011.e1-4.

Hornung R, Neubauer H, Gall C, Vogel U, Wallwiener D, Solomayer E, Fehm T. Changes in tumour biological markers during primary systemic chemotherapy (PST). *International Institute of Anticancer Research* 2008; 28:1797-1804.

Krainick-Strobel U, Wallwiener D, Hoffmann J, Meyberg-Solomayer G, Doser M, Hierlemann H, Huober J, Fehm T, Gruber I, Krämer B, Gall C, Huber B, Majer I, Hahn M. Development of a gel-simulation model and generation of standard tables for the complete extirpation of benign breast lesions with vacuum assisted biopsy under ultrasound guidance. *Ultrasound in medicine & biology* 2006; 32:1539-44.

Solomayer E, Huober J, Wallwiener D, Neubauer H, Vogel U, Krämer B, Bachmann R, Pergola-Becker G, Becker S, Fehm T. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. *Breast cancer research and treatment* 2006; 98:179-84.

Schneeweiss A, Bastert G, Huober J, Wallwiener D, Hamerla R, Lichter P. Neoadjuvant therapy with gemcitabine in breast cancer. *Oncology (Williston Park, N.Y.)* 2004; 18:27-31.

Huober J, Krainick-Strobel U, Kurek R, Wallwiener D. Neoadjuvant endocrine therapy in primary breast cancer. *Clinical breast cancer* 2004; 5:341-7.

Volkman M, Zentgraf H, Fiehn W, Wallwiener D, Bastert G, Hänsel S, Ludwig J, Hajar Y, Frey M, Gangel D, Sinn H, Huober J. Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression. *Oncology* 2002; 63:297-305.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch